vs
Side-by-side financial comparison of AbbVie (ABBV) and Nike, Inc. (NKE). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($15.0B vs $11.3B, roughly 1.3× Nike, Inc.). AbbVie runs the higher net margin — 4.6% vs 4.6%, a 0.0% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (9.9% vs 0.1%). Over the past eight quarters, AbbVie's revenue compounded faster (1.8% CAGR vs -5.4%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Nike often refers to:Nike, Inc., a major American producer of athletic shoes, apparel, and sports equipment Nike (mythology), a Greek goddess who personifies victory
ABBV vs NKE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0B | $11.3B |
| Net Profit | $697.0M | $520.0M |
| Gross Margin | — | 40.2% |
| Operating Margin | 26.6% | — |
| Net Margin | 4.6% | 4.6% |
| Revenue YoY | 9.9% | 0.1% |
| Net Profit YoY | -46.0% | -34.5% |
| EPS (diluted) | $0.39 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $15.0B | $11.3B | ||
| Q4 25 | $16.6B | $12.4B | ||
| Q3 25 | $15.8B | $11.7B | ||
| Q2 25 | $15.4B | $11.1B | ||
| Q1 25 | $13.3B | $11.3B | ||
| Q4 24 | $15.1B | $12.4B | ||
| Q3 24 | $14.5B | $11.6B | ||
| Q2 24 | $14.5B | $12.6B |
| Q1 26 | $697.0M | $520.0M | ||
| Q4 25 | $1.8B | $792.0M | ||
| Q3 25 | $186.0M | $727.0M | ||
| Q2 25 | $938.0M | $211.0M | ||
| Q1 25 | $1.3B | $794.0M | ||
| Q4 24 | $-22.0M | $1.2B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.4B | $1.5B |
| Q1 26 | — | 40.2% | ||
| Q4 25 | 72.6% | 40.6% | ||
| Q3 25 | 66.4% | 42.2% | ||
| Q2 25 | 71.8% | 40.3% | ||
| Q1 25 | 70.0% | 41.5% | ||
| Q4 24 | 70.9% | 43.6% | ||
| Q3 24 | 70.9% | 45.4% | ||
| Q2 24 | 70.9% | 44.7% |
| Q1 26 | 26.6% | — | ||
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 31.7% | 2.9% | ||
| Q1 25 | 28.0% | 7.5% | ||
| Q4 24 | -9.9% | 11.5% | ||
| Q3 24 | 26.5% | 11.3% | ||
| Q2 24 | 27.6% | 13.7% |
| Q1 26 | 4.6% | 4.6% | ||
| Q4 25 | 10.9% | 6.4% | ||
| Q3 25 | 1.2% | 6.2% | ||
| Q2 25 | 6.1% | 1.9% | ||
| Q1 25 | 9.6% | 7.0% | ||
| Q4 24 | -0.1% | 9.4% | ||
| Q3 24 | 10.8% | 9.1% | ||
| Q2 24 | 9.5% | 11.9% |
| Q1 26 | $0.39 | $0.35 | ||
| Q4 25 | $1.02 | $0.53 | ||
| Q3 25 | $0.10 | $0.49 | ||
| Q2 25 | $0.52 | $0.14 | ||
| Q1 25 | $0.72 | $0.54 | ||
| Q4 24 | $-0.03 | $0.78 | ||
| Q3 24 | $0.88 | $0.70 | ||
| Q2 24 | $0.77 | $0.99 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $8.1B |
| Total DebtLower is stronger | — | $8.0B |
| Stockholders' EquityBook value | — | $14.1B |
| Total Assets | — | $37.1B |
| Debt / EquityLower = less leverage | — | 0.57× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $8.1B | ||
| Q4 25 | $5.3B | $7.0B | ||
| Q3 25 | $5.7B | $7.0B | ||
| Q2 25 | $6.5B | $7.5B | ||
| Q1 25 | $5.2B | $8.6B | ||
| Q4 24 | $5.6B | $8.0B | ||
| Q3 24 | $7.3B | $8.5B | ||
| Q2 24 | $13.2B | $9.9B |
| Q1 26 | — | $8.0B | ||
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | $8.0B | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | $8.9B |
| Q1 26 | — | $14.1B | ||
| Q4 25 | $-3.3B | $14.1B | ||
| Q3 25 | $-2.6B | $13.5B | ||
| Q2 25 | $-183.0M | $13.2B | ||
| Q1 25 | $1.4B | $14.0B | ||
| Q4 24 | $3.3B | $14.0B | ||
| Q3 24 | $6.0B | $13.9B | ||
| Q2 24 | $6.8B | $14.4B |
| Q1 26 | — | $37.1B | ||
| Q4 25 | $134.0B | $37.8B | ||
| Q3 25 | $133.9B | $37.3B | ||
| Q2 25 | $137.2B | $36.6B | ||
| Q1 25 | $136.2B | $37.8B | ||
| Q4 24 | $135.2B | $38.0B | ||
| Q3 24 | $143.4B | $37.9B | ||
| Q2 24 | $141.9B | $38.1B |
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | 0.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
